Iloprost: new indication.  Not adequately assessed.
(1) Iloprost, a vasodilatory prostacyclin analogue administered by infusion, is indicated for second-line therapy in patients with severe ischaemia of the lower limbs, when surgical revascularisation fails or is contraindicated. (2) In thromboangiitis obliterans the clinical file on iloprost has remained inadequate since the product was first released. (3) A meta-analysis of 6 clinical trials giving conflicting results in patients with stage III or IV lower-limb arterial disease favoured iloprost.  But the results of this meta-analysis are uninterpretable because of methodological biases.  It is not known what effects iloprost has in the short term (on pain and skin damage) or in the long term (on the risk of amputation). (4) The iloprost dose must be adjusted individually according to adverse effects linked to vasodilation.
D002986:Clinical Trials as Topic; D005602:France; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy; D007866:Leg / Q000098:blood supply; D015201:Meta-Analysis as Topic; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D014665:Vasodilator Agents; D016285:Iloprost